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ABSTRACT Investigation of Candida yeast prevalence in patients with psoriasis 
has been performed with the aim of determining their possible role as a trigger 
factor in the pathogenic process of this disease. The purpose of our study was 
to investigate the prevalence of Candida species on the skin of intertriginous 
areas and psoriasis lesions as well as the prevalence of Candida species in the 
stool of patients with psoriasis. This study also examines a possible correlation 
between the severity of psoriasis and prevalence of isolated Candida species. 
The patients with psoriasis were divided into two groups according to the clini-
cal type of psoriasis; a group with plaque psoriasis (PP) and psoriasis inversa 
(PI) (G1) and a group with psoriasis erythrodermica (PE) and psoriasis pustulosa 
(PPS) (G2). The group of patients with PP and PI (G1) was divided according to 
score on the Psoriasis Area Severity Index test (PASI) according to severity of 
disease into the clinical subgroup with PASI <50 and another subgroup with 
PASI >50. Mycological analysis of skin samples in patients of the clinical group 
with PP and PI showed a statistically significant difference as well as correlation 
between the results of isolated specimens of Candida species from the skin of 
intertriginous areas and psoriasis lesions, the clinical form of psoriasis, and the 
PASI score.
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INTRODUCTION
Psoriasis is a chronic, relapsing inflammatory skin 
disease characterized by abnormal keratinocyte dif-
ferentiation and proliferation. Besides genetic predis-
position, many endogenous and exogenous provok-
ing factors play an important role in the development 
of the disease. Infections have been recognized as a 
trigger for the onset or exacerbation of psoriasis (1,2). 
Several studies suggested that various micro-organ-
isms such as β-hemolytic Streptococcus, Staphylococ-
cus aureus and Candida albicans may release factors 
that act as superantigens and thus stimulate the 
pathogenic process of psoriasis. Superantigens are 
the microbial proteins which are able to stimulate up 
to 20% of the naive T-cell population in a nonspecific 
way (3,4). It is thought to play an important role in the 
pathogenesis of inflammatory skin and systemic dis-
eases, such as psoriasis, atopic dermatitis, vasculitis, 
T-cell lymphoma, and autoimmune diseases. The role 
of the superantigens in the pathogenesis of these dis-
eases is determined by its ability to cause extensive 
inflammatory cytokine release after stimulation of T-
cell and/or T-lymphocyte-mediated cytotoxicity, and 
thus damage to the tissue. Activation and infiltration 
of T-lymphocytes play a key role in the development 
and maintenance of psoriasis (5). The purpose of 
this study was to determine the prevalence of Can-
dida species on the skin and in the intestinal tract of 
patients with psoriasis and to determine if there is a 
correlation between severity of psoriasis with the test 
results of isolated Candida species samples. 
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PATIENTS AND METHODS
Patients
The study included 80 patients with different clini-
cal types of psoriasis (29 women and 51 men, median 
age 45.8 years). According to the clinical type of pso-
riasis, the patients were divided into two groups, a 
group with plaque psoriasis (PP) and psoriasis inversa 
(PI) (G1) and a group with psoriasis erythrodermica 
(PE) and psoriasis pustulosa (PPS) (G2). The group of 
patients with PP and PI was divided according to the 
Psoriasis Area Severity Index (PASI) score, according to 
severity of disease into the subgroups with PASI score 
less than 50 (G1A) and PASI score more than 50 (G1B). 
Patients with psoriasis were excluded from the study 
if they had received systemic or topical antimicrobial 
or immunosuppressive treatment during the preced-
ing three months or if they had a previous diagnosis 
of diabetes mellitus. 
 
Methods
All included patients with psoriasis gave their 
medical history; clinical examination of skin changes 
was conducted and clinical tests were performed 
– the auxiliary physical search method specific for 
psoriasis. Skin samples from psoriatic lesions and in-
tertriginous areas as well as stool samples for fungal 
cultures were taken from all the study participants. In 
patients with psoriasis inversa, samples for mycologi-
cal analysis were taken both from the skin folds with 
psoriatic lesions and from skin lesions suspected of 
intertriginous candidiasis.
Laboratory analysis
Skin samples from the intertriginous areas and 
psoriatic lesions, and stool samples were taken using 
a sterile cotton-tipped swab. Collected samples were 
inoculated separately into Sabouraud dextrose agar 
plates with the addition of antibiotics to prevent bac-
terial growth. Sabouraud dextrose agar plates were 
incubated at 37°C and examined for 48 hours. After 
this period, the plates with cultures were inspected 
and selected as positive and negative and with and 
without yeast growth. In this way, the isolation of 
yeasts was performed and the number of colonies 
on plates with inoculated stool samples was deter-
mined. A germination test was used for identification 
of C. albicans and its differentiation from non-C. albi-
cans species. All yeast isolates were classified in two 
groups: C. albicans species (CA) and non-C. albicans 
(NCA) species, without individual identification of 
non-C. albicans species.
Statistical analysis
Analysis of statistical data was conducted using 
the Chi-square test and Pearson test of correlation at 
the level of 95% significance. All statistical calculation 
was done using the SPSS computer program,  version 
13 for Microsoft Windows (SPSS Inc, Chicago, Illinois, 
USA).
RESULTS
A total of 60 patients were included in the group 
with PP and PI (G1), and 20 patients were included 
in the G2 group with atypical clinical types of pso-
riasis (PE and PPS) (Table 1, Table 2). The average age 
among the total of 80 patients was 45.8 years±16.2, 
with the youngest patient at age 9 and the oldest at 
age 75. Statistical analysis did not find significant dif-
ferences in age of patients between the two clinical 
groups (G1 and G2 groups), (x²=5.190, P>0.05).
Table 1. Distribution of patients according to clini-







G1 PP+PI 60 75.0
G2 PE+PPS 20 25.0
Total 80 100.0
 G1 (PP: plaque psoriasis, PI: psoriasis inversa); G2 (PE: 
psoriasis erythrodermica, PPS: psoriasis pustulosa)
Mycological analysis of skin samples
The swab findings from the skin of all patients in 
clinical group G1 (PP and PI) and G2 (PE and PPS) are 
presented in Table 3 and Figure 1. 
Positive isolates from the skin of intertriginous ar-
eas and psoriatic lesions were found in 33.3% of pa-
tients with PP and PI and with PASI <50 (G1A). In the 
group of patients with the severe clinical type of pso-
riasis with PASI >50 (G1B), there were 33.3% positive 
isolates from the skin (Figure 1). We found a statisti-
cally significant difference between the findings of 
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Table 2. Distribution of patients according to clini-






n % n % n %
<50 (G1A) 32 65.3 7 63.6 39 65.0
>50 (G1B) 17 34.7 4 36.4 21 35.0
Total 49 100.0 11 100.0 60 100.0
PASI: Psoriasis Area Severity Index
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the skin swab (including both intertriginous regions 
and psoriatic lesions) and the clinical type of PP and 
PI with PASI <50, and the same clinical type of dis-
ease with PASI >50 (x²=15.83, P<0.014). Furthermore, 
statistical analysis revealed a significant correlation 
between the skin swab findings (including both in-
tertriginous regions and psoriatic lesions), clinical 
disease type G1 patient group (PP and PI) and the 
PASI score, in the sense that in severe clinical types 
with higher PASI scores there were more positive iso-
lates of Candida species; Ro=0.378, P=0.018 (P<0.05). 
There was no statistically significant difference or cor-
relation between findings of skin swabs (intertrigi-
nous regions and psoriatic lesions) of the two clinical 
groups, G1 and G2 (P>0.05). 
albicans species. Mixed cultures (CA and NCA) were 
isolated in 3.7% patients. Statistical analysis showed 
no significant difference between mycological find-
ings from the stool between the two clinical groups 
(G1 and G2), (P>0.05).
Results of stool mycological findings in patients 
from the clinical group with PP and PI (G1) according 
to the severity of clinical symptoms assessed using 
the PASI test are presented in Table 4. We did not find 
significant differences between the mycological find-
ings in the stool for patients with PP and PI with PASI 
<50 and the same clinical type of psoriasis with PASI 
>50 (P>0.05). Furthermore, there was no statistically 
significant correlation between the mycological find-
ings in the stool, clinical form of disease (PP and PI), 
and the PASI score (P>0.05).
DISCUSSION
A combination of genetic and numerous endog-
enous and exogenous factors are responsible for 
psoriasis occurrence and detection of the disease 
(6). Newer hypotheses on the pathogenesis of pso-
riasis are based on the dominant role of the cellular 
immune system in exacerbation of the disease (7). 
Many authors believe that microorganisms such as 
β-hemolytic Streptococcus, Staphylococcus aureus, 
and Candida albicans can act as exogenous triggers 
and release factors which act as superantigens. The 
source of these microorganisms may be in the skin or 
in other parts of the body such as the gut, in case of 
the Candida species. From this location, Candida and 
another microorganisms release their superantigens 
that reach the skin through the vascular system and 
start the psoriatic process (8). Sayama et al. concluded 
Figure 1. The skin swab findings of in patients from clinical 
group G1 (PP and PI) – correlation with severity of disease.
Table 3. The prevalence of Candida species on the 
skin of intertriginous areas and psoriatic lesions 












n % n % n %
Neg 40 66.7 13 65.0 53 66.3
CA 9 15.0 3 15.0 12 15.0
NCA 11 18.3 4 20.0 15 18.7
Total 60 100.0 20 100.0 80 100.0
Neg: negative findings; CA: Candida albicans; NCA: non-
Candida albicans
Table 4. Mycological stool findings in patients in 





Clinical group tTotal    
isolates 
findingsG1A G1B
PASI <50 PASI >50
n % n % n %
Neg 23 59,0 7 33,3 30 50,0
CA 11 28,2 11 52,4 22 36,7
NCA 3 7,7 3 14,3 6 10,0
CA+NCA 2 5,1 0 0,0 2 3,3
Total 39 100,0 21 100,0 60 100,0
G1 (PP: Plaque psoriasis, PI: Psoriasis inversa); G1A (clinical 
form PP and PI, with PASI <50); G1B (clinical form PP and PI, 
with PASI >50)
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Results of the mycological findings in the 
stool samples
In the total sample of 80 patients, 52% had posi-
tive findings in the stool, out of which 38.8% isolates 
were C. albicans and 10.0% were isolates of non-C. 
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that superantigens may be factors for exacerbations 
or “triggers” of psoriasis, but they are not essential for 
disease maintenance (9). Very small amounts of data 
in the available literature indicate the prevalence of 
Candida yeasts in patients suffering from psoriasis, 
especially the prevalence in intertriginous areas of 
the skin and in psoriatic lesions, so this was one of 
the initial factors that encouraged us to engage in 
this study. It was suggested that cutaneous or in-
testinal Candida is a trigger of plaque psoriasis (10). 
Based on this, the results of some studies showed 
that systemic antifungal treatment with ketokonazol 
or nystatin was very effective in some patients with 
psoriasis (11). During analysis of the microflora in 297 
patients suffering from psoriasis, Noah found more 
than 30 different microorganisms in psoriatic skin 
lesions, including the yeast C. albicans and C. parap-
silosis (12). Rosenberg et al. have explored the asso-
ciation between microorganisms and psoriasis in 167 
patients with psoriasis, and isolated an insignificant 
number of Candida yeasts in a skin fold (13). Flyström 
et al. investigated the presence of microorganisms on 
the intertriginous areas of the skin in patients with 
inverse psoriasis (“intertriginous psoriasis”). Candida 
was not isolated from the intertriginous skin region; 
none of the patients from the three groups studied 
was positive (1).
In our study, analysis of mycological findings from 
the skin of intertriginous areas and psoriatic lesions in 
patients with PP and PI, with PASI <50 and PASI >50, 
showed a statistically significant difference and cor-
relation between the swab findings, clinical form of 
disease, and severity of the disease determined by 
PASI. In patients with PI and with PASI >50, there were 
no negative mycological findings from the skin of 
intertriginous areas, which was expected due to the 
pronounced tendency of this form of exudation and 
additional superinfection. 
Henel et al. conducted tests on the incidence of 
Candida species in the stool of patients with psoriasis; 
these studies were based on the assumption that the 
intestinal Candida may be a “trigger” factor of psoria-
sis (14). The study of Menzel and Holzman found Can-
dida yeasts in 92.0% of patients, while the prevalence 
of Candida was 50.0% in the control group (15). In 
our study, Candida was isolated in the stool of 52.2% 
patients, and Candida albicans dominated at 38.8%. 
There was higher prevalence of Candida species in 
the stool of patients with PE and PPS (60.0%). There 
was no statistically significant difference between the 
mycological findings in the stool and clinical findings 
in the group of patients with PP and PI and the group 
of patients with PE and PPS.
Analysis of the prevalence of Candida species in 
the stool of patients with PP and PI with PASI <50 and 
PASI >50 showed a higher prevalence of Candida in 
patients with the severe clinical form of the disease 
(PASI >50) (66.6%). Statistical analysis showed no sig-
nificant difference between the mycological findings 
for Candida in the stool, the clinical form of psoriasis, 
and PASI score. In the study conducted by Waldman 
et al. which included 50 patients with psoriasis , Can-
dida was isolated in the stool of 72% of patients (16). 
C. albicans was isolated at the highest percentage, 
namely 64.0%. The authors of this study did not find 
a correlation between disease severity assessed by 
PASI score and quantitative analysis of Candida in the 
stool of patients with psoriasis, which is similar to the 
results of our study.
CONCLUSION
This study revealed a significant association be-
tween psoriasis and Candida and also showed that 
the frequency of Candida species in the stool was 
higher than the frequency of Candida species on 
the skin of intertriginous areas and psoriasis lesions. 
Further studies are needed to establish whether the 
frequency of isolated Candida species correlates with 
the degree of severity of psoriasis. Use of new mo-
lecular methods applied to more patients is needed 
to clarify the involvement of Candida in the develop-
ment or exacerbation of psoriasis. However, our stud-
ies suggest that an antifungal treatment should be 
considered as an adjuvant treatment in patients with 
psoriasis that have a significant quantity of Candida 
in the stool.
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